Results 1 to 10 of about 13,248 (184)

In Vitro Activities of Ceftazidime–Avibactam and Aztreonam–Avibactam at Different Inoculum Sizes of Extended-Spectrum β-Lactam-Resistant Enterobacterales Blood Isolates

Antibiotics, 2021
β-lactam–avibactam combinations have been proposed as carbapenem-sparing therapies, but little data exist on their in vitro activities in infections with high bacterial inocula.
Moonsuk Bae, Taeeun Kim, Joung Ha Park, Seongman Bae, Heungsup Sung, Mi-Na Kim, Jiwon Jung, Min Jae Kim, Sung-Han Kim, Sang-Oh Lee, Sang-Ho Choi, Yang Soo Kim, Yong Pil Chong   +12 more
doaj   +2 more sources

Physicochemical Stability of Aztreonam/Avibactam in Elastomeric Devices for Outpatient Parenteral Antimicrobial Therapy [PDF]

Antibiotics
Background/Objectives: Outpatient Parenteral Antimicrobial Therapy (OPAT) programs provide a safe and cost-effective strategy for administering intravenous antimicrobials in the home setting.
Cristina Toro Blanch, Xabier Larrea Urtaran, Raquel Aguilar Salmerón, Alba Prat Riera, Laura Gómez, Anna Costa Pou, Beatriz Fernández-Rubio, Laura Herrera-Hidalgo, Carles Quiñones Ribas   +8 more
doaj   +2 more sources

Outbreak of aztreonam–avibactam-resistant NDM-5-producing Escherichia coli isolates in a hospital of Paris [PDF]

Microbiology Spectrum
The emergence of aztreonam–avibactam resistance among NDM-producing Escherichia coli represents a major therapeutic and infection control concern. Four cases of aztreonam–avibactam-resistant (AZAR) NDM-producing E.
Véronique Faraut Derouin, Bérénice Souhail, Caroline Charlier, Sébastien Gaultier, Etienne Canoui, Anne Sorieul, Daria Menuet, Hélène Poupet, Laurence Armand-Lefèvre, Eve-Marie Walle, Delphine Desbois, Alexandra Doloy, Philippe C. Morand, Claire Poyart, Romain Coriat, Asmaa Tazi, Hedi Mammeri   +16 more
doaj   +2 more sources

The Revival of Aztreonam in Combination with Avibactam against Metallo-β-Lactamase-Producing Gram-Negatives: A Systematic Review of In Vitro Studies and Clinical Cases

Antibiotics, 2021
Infections caused by metallo-β-lactamase (MBL)-producing Enterobacterales and Pseudomonas are increasingly reported worldwide and are usually associated with high mortality rates (>30%).
Stefano di Bella, Luigi Principe, Alberto Enrico Maraolo   +2 more
exaly   +3 more sources

Evaluating the efficacy of ceftazidime/avibactam plus amikacin combination therapy as a carbapenem-sparing agent against ceftazidime/avibactam-resistant Escherichia coli using a hollow fiber infection model: a proof-of-concept study [PDF]

Antimicrobial Agents and Chemotherapy
Carbapenems, often regarded as the last line of defense in treatment of urinary tract infections and urosepsis caused by Escherichia coli, are under pressure from emerging resistance.
Mikaela M. Walker, Jason A. Roberts, Yixuan Li, Saiyuri Naicker, Steven C. Wallis, Jenny L. Ordonez, Hayoung Won, Brian M. Forde, Fekade B. Sime   +8 more
doaj   +2 more sources

Ceftazidime-avibactam [PDF]

Revista Española de Quimioterapia, 2021
Ceftazidime is a 3rd generation cephalosporin active against Pseudomonas aeruginosa. Avibactam is an inhibitor of class A, C and some class D β-lactamases. The antibacterial spectrum of ceftazidime-avibactam covers 95% of P. aeruginosa isolates and >99% of enterobacteria, including strains carrying extended-spectrum β-lactamases (ESBLs).
Matesanz, Mayra, Mensa, José
openaire   +2 more sources

In vitro Optimization of Ceftazidime/Avibactam for KPC-Producing Klebsiella pneumoniae

Frontiers in Microbiology, 2021
Ceftazidime/avibactam is an important treatment option for infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae (KPC-Kp), however, resistance can emerge during treatment.
Yanqin Huang, Tiffany Wu, Omar Perez, Amisha P. Rana, Liang Chen, Liang Chen, Barry N. Kreiswirth, Michael J. Satlin, Zackery P. Bulman   +8 more
doaj   +1 more source

Cefdinir and β-Lactamase Inhibitor Independent Efficacy Against Mycobacterium tuberculosis

Frontiers in Pharmacology, 2021
Background: There is renewed interest in repurposing β-lactam antibiotics for treatment of tuberculosis (TB). We investigated efficacy of cefdinir, that withstand the β-lactamase enzyme present in many bacteria, against drug-susceptible and multi-drug ...
Shashikant Srivastava, Shashikant Srivastava, Tania Thomas, Dave Howe, Lesibana Malinga, Prithvi Raj, Jan-Willem Alffenaar, Jan-Willem Alffenaar, Jan-Willem Alffenaar, Tawanda Gumbo, Tawanda Gumbo   +10 more
doaj   +1 more source

Synergistic Effect of Clinically Available Beta-Lactamase Inhibitors Combined with Cefiderocol against Carbapenemase-Producing Gram-Negative Organisms

Antibiotics, 2022
The role of β-lactamases in reduced susceptibility or resistance to cefiderocol has been supported by recent reports. The purpose of this study was to investigate the in vitro impact of clinically available β-lactamase inhibitors on cefiderocol activity ...
Gabriele Bianco, Paolo Gaibani, Sara Comini, Matteo Boattini, Giuliana Banche, Cristina Costa, Rossana Cavallo, Patrice Nordmann   +7 more
doaj   +1 more source

A New Twist: The Combination of Sulbactam/Avibactam Enhances Sulbactam Activity against Carbapenem-Resistant Acinetobacter baumannii (CRAB) Isolates

Antibiotics, 2021
An increasing number of untreatable infections are recorded every year. Many studies have focused their efforts on developing new β-lactamase inhibitors to treat multi-drug resistant (MDR) isolates. In the present study, sulbactam/avibactam and sulbactam/
Fernando Pasteran, Jose Cedano, Michelle Baez, Ezequiel Albornoz, Melina Rapoport, Jose Osteria, Sabrina Montaña, Casin Le, Grace Ra, Robert A. Bonomo, Marcelo E. Tolmasky, Mark Adams, Alejandra Corso, Maria Soledad Ramirez   +13 more
doaj   +1 more source